FluroTech Appoints Aurora's Former Chief Scientist Dr. MacMillan as Director of Scientific Research and Business Development
Calgary, Alberta--(Newsfile Corp. - September 18, 2018) - FluroTech Ltd. (TSXV: TEST), ("FluroTech" or the "Company"), is pleased to announce the appointment of Dr. Trevor MacMillan as Director of Scientific Research and Business Development. With prior industry experience at Aurora Cannabis Inc., Dr. MacMillan brings with him an impressive background in plant breeding, biotechnology regulatory environments and quality control. He will be an integral part of FluroTech's scientific and business development teams.
"Dr. MacMillan brings a unique perspective of the Licensed Producers' needs in the realm of quality control, testing and analytics in the cannabis industry. With his depth of knowledge, we can better serve our customers as we bring our flagship product, CompleTestTM, to market this fall and biomarking technology in 2019," commented Danny Dalla-Longa CEO of FluroTech.
"FluroTech has developed an elegant solution to simplify cannabis quality control testing. I'm excited about helping the cannabis industry produce safer, higher quality products with FluroTech's technology. It's a game changer," stated Trevor. "Additionally, their biomarking technology represents a low cost and unique way to perform seed to sale product tracking that will solve the issues that exist with current solutions."
Dr. MacMillan graduated from the University of Saskatchewan with a bachelor of science in biochemistry in 2001. In 2014, he completed his PhD in agricultural plant biotechnology at the University of Lethbridge. His postgraduate career began with Agriculture and Agri-Food Canada and Health Canada in waterborne photogene isolation and characterization. Following this period, Dr. MacMillan was previously employed by the Department of National Defence at Defence Research and Development Canada (DRDC) where he was instrumental in developing molecular detection assays for bacterial bio-threat agents. Additionally, he worked as the good laboratory practices (GLP) implementation co-ordinator for DRDC for a GLP-compliant facility performing regulatory drug studies. Later, he was employed by the Canadian Food Inspection Agency (CFIA) as a senior molecular research technologist. His most recent role at Aurora Cannabis Inc. as the Director of Research and Quality Control honed his knowledge of quality testing of cannabis.
FluroTech is a technology and marketing company whose core business is focused on the commercialization of new technologies in the cannabis industry. FluroTech's proprietary spectroscopy-based technology allows for the testing and identification of organic and inorganic compounds contained within biological samples. Using the technology that was developed at the University of Calgary in conjunction with the University of Alberta, FluroTech has developed a two-part solution comprising an instrument called the CompleTest™ and consumable testing kits.
Alistair Ross Technology Centre
Suite 111, 3553-31 Street NW
Calgary, AB T2L 2K7
Chief Executive Officer
IR — Thesis Capital Inc.
Cannot view this image? Visit:
Cautionary Statement Regarding Forward-Looking Information
This news release contains "forward-looking information" within the meaning of Canadian securities legislation. Forward-looking information generally refers to information about an issuer's business, capital, or operations that is prospective in nature, and includes future-oriented financial information about the issuer's prospective financial performance or financial position. The forward-looking information in this news release includes disclosure about the future performance of the Company.
The Company made certain material assumptions, including but not limited to prevailing market conditions and general business, economic, competitive, political and social uncertainties to develop the forward-looking information in this news release. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.
Actual results may vary from the forward-looking information in this news release due to certain material risk factors. These risk factors include, but are not limited to, adverse market conditions and regulatory and other risks associated with the medical cannabis industry in general. The Company cautions that the foregoing list of material risk factors and assumptions is not exhaustive.
The Company assumes no obligation to update or revise the forward-looking information in this news release, unless it is required to do so under Canadian securities legislation.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy of this release.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES